Myocardial viability testing in patients with severe left ventricular dysfunction by SPECT and PET

Ciddi sol ventrikül disfonksiyonu olan hastalarda miyokardiyal canlılığın SPECT ve PET ile değerlendirilmesi

Mehmet Onur Demirkol
Department of Nuclear Medicine and Molecular Imaging, V.K.V. American Hospital, İstanbul, Turkey

ABSTRACT

In this article, the role of nuclear medicine modalities in assessing myocardial viability and risk stratification in patients with advanced left ventricular (LV) dysfunction are reviewed. Diagnosis of reversible LV dysfunction in patients with heart failure is an important clinical issue. Patients with severe LV dysfunction who have viable myocardium are the patients at highest risk because of the potential for ischemia but at the same time benefit most from revascularization. It is important to identify viable myocardium in these patients, and nuclear medicine techniques are an excellent tool for this. Single-photon emission computed tomography (SPECT) in combination with myocardial perfusion tracers plays an important role in the identification of tissue viability in myocardial segments. Imaging with positron emission tomography (PET) tracers allow the assessment of physiologic processes such as myocardial oxygen consumption, metabolic rate of glucose utilization, and myocardial blood flow. Metabolic imaging with PET offers regional tissue viability in patients with advanced coronary artery disease and severely impaired LV function. (Anadolu Kardiyol Derg 2008; 8: Suppl 2; 60-70)

Key words: Myocardial viability, left ventricular dysfunction, single-photon emission computed tomography, positron emission tomography

ÖZET


Anahtar kelimeler: Miyokardiyal canlılık, sol ventrikül disfonksiyonu, tek-foton emisyon bilgisayarlı tomografi, pozitron emisyon tomografisi

Introduction

The prevalence of left ventricular (LV) dysfunction and resultant heart failure is increasing in industrialized countries. Two thirds of cases of left ventricular dysfunction are the result of coronary artery disease (CAD) (1).

Not only are these patients at high risk for subsequent cardiac death, severe morbidities, and recurrent hospitalizations for congestive heart failure, they also frequently have severe limitations in their lifestyles and well-being. Although there have been significant advances in medical therapy for LV dysfunction and resulting symptoms of heart
failure, the prognosis from heart failure remains extremely poor, with an annual mortality ranging from 10% to 50% per year (2). The total number of deaths has risen 148% between 1979 and 2000 (3). Many of these patients had previous myocardial infarctions, the extent of remaining viable tissue is of clinical interest, and also related to prognosis (4).

The need for making the diagnosis of resting ischemia, hibernation, or stunning stems from their role in exacerbating LV dysfunction, heart failure symptoms sudden death, hemodynamic deterioration and from the need to decide between revascularization and cardiac transplantation.

Several clinical studies have shown that myocardial dysfunction in patients with CAD may be reversible (5). After an initial ischemic injury, various processes can occur that lead to LV dysfunction, including LV remodeling, impairment of energetics, myocyte dysfunction, and cell death via necrosis and/or apoptosis. Other than cell death, these processes are, to an extent, reversible, and LV function often can be improved, resulting in better patient outcome. Although medical therapy can be extremely beneficial, revascularization in the appropriate patient often is the best therapy (6).

Left ventricular dysfunction, in some cases, is the result of “stunned myocardium,” which is defined as myocardium that has become dysfunctional because of a transient coronary occlusion, has been salvaged by coronary reperfusion, yet exhibits prolonged but transient postischemic dysfunction, lasting hours to weeks (7). Thus, in myocardial stunning, blood flow has been restored but contraction has not returned to baseline, i.e., there is a flow-contraction mismatch.

Left ventricular dysfunction, in other cases, is the result of “hibernating myocardium.” Rahimtoola et al. (8), introduced this term to refer to persistent LV dysfunction in the presence of severe CAD that is reversible after revascularization. The pathophysiology underlying these phenomena is thought to reflect the down-regulation of function in the presence of reduced blood flow and oxygen supply (8, 9). By this definition, hibernating myocardium is a flow-contraction match. Some investigators contend that hibernating myocardium is actually a manifestation of repetitive myocardial stunning (10). Table 1 summarizes different properties of stunned and hibernating myocardium.

Regardless of the mechanism, it is important to identify hibernating myocardium because ventricular function will generally improve after revascularization or other therapies.

### Table 1. Properties of different myocardial viability patterns

<table>
<thead>
<tr>
<th>Property</th>
<th>Hibernation</th>
<th>Stunned</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPS (uptake)</td>
<td>&gt; 50%</td>
<td>Normal</td>
</tr>
<tr>
<td>Blood flow</td>
<td>Diminished</td>
<td>Normal</td>
</tr>
<tr>
<td>Wall motion</td>
<td>Abnormal</td>
<td>Abnormal</td>
</tr>
<tr>
<td>FDG uptake</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fatty acid metabolism</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Response to cathecholamines</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Oxygen consumption</td>
<td>Diminished</td>
<td>Normal or increased</td>
</tr>
</tbody>
</table>

FDG—fluorodeoxyglucose
MPS—myocardial perfusion scintigraphy

Clinical importance of identifying viable myocardium in patients with severe left ventricular dysfunction

Patients with depressed LV systolic function have a worsened prognosis. In the CASS (Coronary Artery Surgery Study) registry, for the cohort of patients treated with medical therapy, those with a LV ejection fraction (EF) of 50% or greater had a 10-year survival of approximately 90%, compared with a survival of 60% for those with an EF of 35% to 49%, and a survival of 30% for those with an EF less than 35% (p<0.001) (11). Publications have consistently shown that among patients with abnormal LV systolic function, those with hibernating myocardium, have the poorest prognosis if they are not referred for a revascularization procedure.

For example, Di Carli et al. (12) performed positron emission tomography (PET) imaging on 93 consecutive patients with coronary artery disease and a mean LV EF of 25%. Medically treated patients who had PET evidence of myocardial viability had markedly lower annual survival of 50%, compared with 92% for patients without evidence of viability (p=0.007). Patients with evidence of myocardial viability who underwent revascularization had a higher survival rate than those treated medically (88% versus 50%, p=0.03) (12).

In a meta-analysis of 3088 patients with decreased EF who underwent a viability study using a variety of methods, Alman et al. reported that the yearly death rate for patients with viability who were treated medically was 16%, compared with 3.2% for patients who underwent revascularization (p<0.0001) (13). Revascularization improved survival for patients with viable myocardium by 79.6%. This pattern maintained regardless of the technique that was used to assess myocardial viability. Conversely, for patients without viable myocardium, there was a trend toward increased mortality in patients who underwent revascularization, 7.7% versus 6.2% (p=0.23) (13).

Haas et al. (14) studied 76 patients with advanced LV dysfunction who were being considered for coronary bypass surgery. Compared with patients who were first evaluated for viability with PET imaging, patients sent to surgery who did not have a viability assessment had a significantly worsened postoperative course, including a lower 12-month survival rate, 79% versus 97% (p=0.01). This study concluded that the forgoing of a viability study resulted in too many high-risk patients without viability being sent for bypass surgery, resulting in a worsened prognosis (14).

Schinkel et al. (15) evaluated multiple imaging techniques in assessment of myocardial viability in patients with heart failure. They reported, in general, nuclear imaging techniques have a high sensitivity for the detection of viability, whereas techniques evaluating contractile reserve have a somewhat lower sensitivity and a higher specificity. Patients with a substantial amount of dysfunctional but viable myocardium are likely to benefit from coronary revascularization and may show improvements in regional and global contractile function, symptoms, exercise capacity, and long-term prognosis (15).
SPECT Perfusion Tracers

Thallium-201 imaging

There are numerous methods proposed to assess myocardial viability with thallium-201 (Tl-201), a radionuclide tracer that assesses not only myocardial perfusion but also myocyte cell membrane integrity. Bax et al. (16) analyzed 33 studies with over 800 patients in a meta-analysis and found that Tl-201 imaging using rest and stress protocols had a sensitivity of 86% and a specificity of 59% in predicting functional recovery following revascularization. The relatively low specificity may reflect the criteria used to classify viability as well as the protocol of data acquisition. In addition, a patient may have sufficient myocardial viability in a region to benefit prognostically with revascularization without necessarily being accompanied by an improvement in ventricular systolic function.

In 1976, Pohost et al. (17) first describe the use of TI-201 redistribution as marker of viable tissue. Some investigators proposed to monitor the redistribution process over prolonged time periods. Gutman et al. (18) reported that in the presence of severe stenoses, defects that appeared fixed at 3 to 5 hours often displayed redistribution after 24 hours. Kiat et al. (19) demonstrated subsequently that the redistribution pattern at 24 hours is more predictive for tissue recovery after revascularization than 3- to 4-hour data.

Although the presence of redistribution has been shown to serve as specific marker of viability, the absence of redistribution at 3 to 4 hours after tracer injection does not rule out tissue viability. Because the quality of 24-hour delayed images often is poor as a result of low counts, a new method of viability assessment was sought (2). In 1990, Dilsizian et al. reported on the technique of TI-201 reinjection (20). In patients with fixed defects or redistribution images, immediately following acquisition of the delayed images, an additional dose of TI-201 was injected at rest. It was observed that 49% of irreversible defects demonstrated normal thallium uptake after the second injection of thallium (Fig. 1). Of myocardial segments with defects on redistribution images that were identified as viable by reinjection studies, 87% had normal thallium uptake and improved regional wall motion after angioplasty. Further studies by the Bonow et al. (21) indicated that TI-201 reinjection imaging has a much greater concordance with Fluorine-18-fluoro-deoxy-glucose (FDG) PET imaging than does conventional TI-201 redistribution, indicating a higher sensitivity for tissue viability by the reinjection procedure. In this study, 88% of viable segments by TI-201 reinjection protocols were also viable based on the FDG-PET studies (21).

Stress perfusion imaging may not be necessary in patients with known CAD who are scheduled for viability studies. Therefore, a number of investigators evaluated the value of rest-delayed thallium imaging as the preferred method for assessing regional tissue viability. In a group of 26 patients with LV dysfunction, Iskandrian et al. found that 12 of 16 patients with normal or transient thallium defects showed improved ventricular function after surgery, whereas 2 out of 10 patients with fixed defects demonstrated some degree of functional recovery (22).

The usefulness of rest-redistribution thallium imaging in identifying myocardial viability was further supported by Ragosta et al, who studied 21 patients with severely depressed LV function (mean EF=27%) who subsequently underwent bypass surgery (23). Myocardial segment viability was assessed both by quantitative analysis of defect severity and the presence of redistribution. Overall, 62% of severely asynergic segments with normal viability and 54% with mildly reduced viability improved function after surgery, compared with only 23% that had severely reduced viability (p=0.002). There was viability in 7 or more of the 15 segments analyzed, mean LVEF increased significantly after bypass surgery.

Besides the predictive value of thallium imaging for tissue recovery after revascularization, the prognostic value of this imaging approach for long-term clinical outcome was investigated by Pagley et al. (24). Seventy patients with multi-vessel CAD and severe LV dysfunction (EF <40%) were imaged prior to bypass surgery. Following surgery, event-free survival was compared in patients with viable versus nonviable revascularized tissue. Patients with a myocardium at least about two thirds viable as measured by a semi-quantitative index had significantly improved 3-year event-free survival as compared with patients who had less viable tissue (24, 25). Thus, rest-delayed thallium imaging can help identify patients who are likely to benefit from bypass surgery.

There are conflicting data in the literature regarding whether defect reversibility or thallium uptake of 50% or greater of peak counts is the best indicator of viability. In a study of 35 patients with LV dysfunction, Sciagra et al. found that tracer activity in a delayed thallium image was important than defect reversibility.
for myocardial viability (26). In contrast, Kitsiou et al. showed that reversible defects more accurately predict functional recovery after revascularization than fixed defects with similar resting tracer activity (27).

For revascularization to improve ventricular function, the ventricle must be ischemic from a stenosis in the artery perfusing the dysfunctional territory (s), and this situation is best depicted by defect reversibility (2). For example, a myocardial region that is dysfunctional from myocardial damage after a non-ST segment elevation infarction and is perfused by a nonstenotic vessel may show sufficient tracer uptake on resting thallium imaging to indicate viability, but will not show improved function after revascularization. In another setting, ventricular contraction may be depressed because of cellular dysfunction related to a cardiomyopathy, in which case one might see satisfactory myocardial thallium uptake, but revascularization would not be expected to improve function. The situation becomes particularly complex in patients who may have both CAD and nonischemic cardiomyopathy, such as diabetics. In these instances, a rest / delayed thallium imaging study may be insufficient, and additional imaging with stress may be needed to identify the presence of myocardial ischemia to decide on revascularization (28). In fact, there is little lost by performing stress/rest-redistribution studies in all patients sent for assessment of myocardial viability as this will not only provide information regarding viability but also provide an assessment of exercise or pharmacologic induced ischemia (2).

In addition to, an elevated TI-201 lung uptake after stress is related to an adverse prognosis. Marcassa et al. (29) found that in patients with severe postischemic LV dysfunction undergoing rest-redistribution thallium imaging, an increased lung tracer uptake showed incremental prognostic value over clinical and other imaging findings, providing clinically useful risk assessment.

**Technetium-99m perfusion tracers**

The vulnerability of TI-201 to attenuation artifacts caused by the relatively lower energy of emitted photons and lower count rates caused by the dose constraints may result in poor or suboptimal images in a significant proportion of studies. Compared with TI-201, technetium-99m (Tc-99m) yields relatively higher energy photons and can be used in much higher doses (30). However, the first-pass extraction fraction of Tc-99m sestamibi and Tc-99m tetrofosmin is lower than that of TI-201 (30). This may be a limitation for the assessment of perfusion at high flow rates but does not effect resting tracer distribution necessary for viability studies. Both Tc-99m labeled tracers are retained in viable myocardium for prolonged time periods (31). Tc-99m sestamibi shows some redistribution in animal studies, which at best is minimal and clinically unimportant in human studies (32).

Myocardial TI-201 uptake occurs through ATPase dependent Na⁺ / K⁺ channels. The cellular uptake of all cationic Tc-99m perfusion agents is similar and is independent of Na⁺ / K⁺ channels. This is mediated by a nonspecific charge dependent transfer of lipophilic cations across the sarcolemma. The uptake of cationic agents is dependent on their lipophilicity. However, requirement of cellular metabolic activity rules out lipophilicity alone as the mechanism for cellular uptake of these tracers. Inside the myocytes, the mitochondria are the predominant site of localization of these cationic agents. Mitochondrial localization of Tc-99m cationic appears to be related to a high negative charge (-165 mV) across the mitochondrial membrane compared with other intracellular organelles. Mitochondrial uptake of these agents requires integrity of their oxidative metabolism. These data support a role for Tc-99m cationic agents as a means of assessing myocardial viability (30).

Properties of single photon emission computed tomography (SPECT) perfusion agents are summarized in Table 2.

| Table 2. Pharmacokinetics of Thallium-201, Tc-99m Sestamibi, and Tc-99m Tetrofosmin |
|---------------------------------|-----------------|-----------------|-----------------|
| Chemical class/charge           | Thallium-201    | Tc-99m sestamibi | Tc-99m tetrofosmin |
| Mechanism of uptake             | Active transport| Passive diffusion| Passive diffusion |
| Myocyte localization            | Cytosol         | Mitochondria    | Mitochondria    |
| Intracellular state             | Free            | Bound           | Bound           |
| Preparation                     | Cyclotron       | Generator/kit   | Generator/kit   |
| First pass extraction fraction  | 85%             | 60%             | 50%             |
| Percent cardiac uptake          | 3%              | 1.5%            | 1.2%            |
| Myocardial clearance            | 4 hr T1/2       | Minimal         | Minimal         |
| Body clearance                  | Renal           | Hepatic         | Hepatic         |
| Imaging time after injection    | 10 min          | 15-30 min       | 5-15 min        |
| Stress                          | 3-4 hrs         | 30-90 min       | 30 min          |

Anadolu Kardiyl Derg
2008: 8: Özel Sayı 2; 60-70
Demirkol M. O.
Myocardial viability by SPECT and PET in LV dysfunction

63
Tc-99m sestamibi imaging

Several studies have shown a relatively good agreement between Tc-99m sestamibi and TI-201 imaging in the same patients. Initial studies comparing Tc-99m sestamibi with TI-201 SPECT imaging suggested an underestimation of tissue viability by Tc-99m sestamibi in up to 47% of segments displaying TI-201 uptake after reinjection (33). Marzullo et al. (34) confirmed these data, reporting a considerable incidence of resting perfusion defects in LV segments with normal resting wall motion but stenosed vascular supply (34).

In contrast, Udelson et al. found that if sestamibi images are interpreted quantitatively, they can predict ventricular function improvement after revascularization. They also observed that uptake of sestamibi paralleled that of TI-201, 1 hour after a resting tracer injection. The likelihood of tissue viability was inversely related to the defect severity of both tracers (35). Similar findings were reported by Kauffman et al. Patients with a mean LV EF of 33% underwent early and 3 hours delayed rest TI-201 imaging, and rest Tc-99m sestamibi imaging. Uptake of both tracers were comparable in myocardial zone of asynergy. Defect magnitude, by quantitation, was similar for 2 tracers for regions with both mild and severe reduction in tracer uptake (36).

Medrano et al. (37), compared regional Tc-99m sestamibi distribution in ischemic myopathic heart removed during heart transplantation. Comparison of in vitro determined Tc-99m sestamibi uptake by autoradiography and histology showed good agreement between tracer uptake and tissue viability. Maes et al. (38) prospectively studied thirty patients with CAD and wall motion abnormalities who were referred for bypass surgery. Each patient underwent rest sestamibi imaging and PET imaging with Nitrogen-13 (N-13) ammonia (a flow agent) and FDG (a metabolic agent), as well as transmural biopsy. Significantly higher sestamibi uptake was found in patients with evidence of viability by PET than in those without. There was a linear relation between sestamibi uptake and fibrosis in the biopsy specimen.

Liu et al. (39) evaluated Tc-99m sestamibi kinetics predict myocardial viability in a perfused rat heart model. They reported that Tc-99m sestamibi myocardial activity is significantly reduced in areas of nonviability after 1 h of tracer uptake and 1 h of tracer clearance. There is a linear correlation between myocardial viability, tracer activity.

Siebelink et al. (40) performed a prospective, randomized study in 103 patients comparing Tc-99m sestamibi SPECT and FDG / ammonia - PET for the management of advanced CAD. The imaging resulted in comparable patient management and event-free survival after revascularization independently of the use of PET and SPECT (40). However, LV EF was less than 30% in only one third of the patients.

Bax et al. (16) summarized 20 viability studies using Tc-99m sestamibi in 488 patients and reported an average sensitivity of 81% and an average specificity of 66%, resulting in a positive and negative predictive value of 71% and 76%, respectively. Most of these studies used a semiquantitative threshold of tracer uptake between 50% and 60% (16).

Sometimes combining stress sestamibi with rest / delayed thallium imaging, in a dual-isotope protocol, can provide a comprehensive assessment of the entire clinical problem. The extent of reversible defects on the stress sestamibi images can assess the myocardial ischemia, while the rest / delayed thallium images can provide additional information on myocardial viability (2). In the case of advanced CAD and severe LV dysfunction, the waiting period for delayed thallium imaging can be prolonged to optimize the viability information.

Pharmacological interventions for viability

Investigations proposed the use of nitrates prior the injection of sestamibi in order to enhance viability information. Nitrates may affect the blood flow pattern by improving trans-stenotic and collateral blood flow to hypoperfused segments (41). The use of this pharmacological intervention results in smaller Tc-99m sestamibi perfusion defects, increasing the sensitivity for detecting viable myocardium. Several protocols of nitrate administration (sublingual, oral, infusion of nitrates) have been proposed, and these have yielded results similar to those achieved with TI-201 viability imaging.

Bisi et al. (42) demonstrated that LV segments, which improved after revascularization, had a 37% decrease of rest perfusion defect size following nitrate application. Scigra et al. (26) observed that nitrate enhanced sestamibi imaging was at least as good as rest / redistribution thallium in detecting viable myocardium and predicting post-revascularization recovery. In the meta-analysis by Bax et al. (16), defect reversibility after nitrate-enhanced sestamibi imaging yielded a sensitivity of 86% and a specificity of 83% in predicting myocardial viability.

Acampa et al. (43) reported that the presence of viable myocardium at nitrate sestamibi SPECT imaging predicts major cardiac events at long-term follow-up and the risk increases with the extent of viability.

Another method to enhance the ability of sestamibi imaging to detect viability is concomitant assessment of ventricular function using gated SPECT imaging. Iskandrian et al. (44) described acquiring gated SPECT images at baseline and during low dose dobutamine infusion, looking not only at tracer uptake, but also at changes in wall motion to assess contractile reserve. Administration of trimetazidine, an agent that improves mitochondrial metabolism, before injecting sestamibi also has been shown to enhance tracer uptake in the dysfunctional but viable myocardium (45).

Tc-99m tetrofosmin imaging

Given its similarity to Tc-99m sestamibi, one would not expect important differences in using Tc-99m tetrofosmin to evaluate myocardial viability in patients with LV dysfunction. Matsunari et al. (46) reported that myocardial tetrofosmin uptake correlated well with thallium uptake on rest delayed images. Gunning et al. (47) found that tetrofosmin imaging was similar to thallium and dobutamine magnetic resonance imaging (MRI) in predicting...
post-revascularization functional recovery. He et al. (48) reported that rest uptake of tetrofosmin in dysfunctional myocardial segments, after administration of sublingual nitrate, correlated with metabolic activity as assessed by FDG. Recently, Giorgetti et al. compared nitrate-enhanced Tc-99m tetrofosmin SPECT with contrast-enhanced MRI (49). The correlation of nitrate-enhanced SPECT images with contrast-enhanced MRI was significantly better than without nitrates. Stollfuss et al. (50) showed that the sensitivity for predicting functional recovery after revascularization assessed by MRI by Tc-99m tetrofosmin SPECT can be improved to 86%, including functional information.

Morishima et al. (51) evaluated risk stratification of patients with prior MI and advanced LV dysfunction by gated Tc-99m tetrofosmin myocardial perfusion SPECT imaging. Their results show that perfusion defect volume by Tc-99m tetrofosmin gated SPECT is the most pivotal predictor of the future occurrence of lethal arrhythmic events and of sudden cardiac death (51).

**Positron emission tomography**

Another strategy for assessment of viability is the addition of metabolic imaging to perfusion imaging using analogues of either glucose or free fatty acids imaging. Under aerobic conditions, the heart uses predominantly fatty acids, but after carbohydrate loading, the inhibitory effect of insulin on release of fatty acids from adipocytes diminishes circulating fatty acids and up-regulates glucose use by the heart. Injured myocardium frequently demonstrates impaired oxidative metabolism, impaired free fatty acid utilization, and an excess of glucose utilization relative to flow (2).

F-18-fluorodeoxyglucose (FDG) is an analogue of glucose, which is transported into cells via a specific glucose membrane transporter and is phosphorylated by hexokinase. Unlike glucose, FDG is trapped and is not metabolized further. Its accumulation is an index of glucose utilization (52).

Myocardial flow can be imaged with N-13 ammonia, oxygen-15 (O-15) water or rubidium-82 chloride (Rb-82) (Table 3). Oxygen-15 water represents a freely diffusible tracer that washes in and out of myocardial tissue as a function of blood flow. The first-pass extraction of O-15 water in the heart is not diffusion limited, nor is O-15 water tissue extraction affected by any metabolic pathways. The second group of flow markers is radiotracers retained in myocardial tissue proportional to myocardial blood flow. For these radiopharmaceuticals, the initial tracer extraction (first-pass extraction) and their tissue retention are important factors defining their suitability as blood flow tracers. N-13 ammonia is highly extracted by myocardial tissue in the form of N-13 ammonia. Within the tissue, the tracer can either back-diffuse into the vascular space or be trapped in the form of N-13 glutamine. Rb-82 displays tracer kinetics similar to those of TI-201. Initial extraction of this compound ranges from 50% to 70%. For both N-13 ammonia retention and Rb-82 chloride extraction, a nonlinear relationship exists between blood flow and tissue tracer extraction (53).

Positron emission tomography has been considered “gold standard” for assessment of myocardial viability using metabolic tracers. The PET criteria of myocardial viability or non-viability are shown in Table 4. With the use of metabolic tracers, several patterns of metabolism can be delineated in combination with knowledge of both perfusion and assessment of regional function to classify myocardium. Normal tissue shows normal function, perfusion and metabolism. Stunned myocardium shows diminished function, preserved flow, and either matched or excessive FDG accumulation. Hibernation has been shown to demonstrate decreased perfusion and function, and relatively preserved or disproportionately increased FDG accumulation. Infarcted myocardium shows a matched decrease in perfusion, function and metabolism (2).

By using information on both blood flow and glucose metabolism, sensitive and specific identification of viable or non-viable myocardium can be performed (Fig. 2). This was first shown by Tillisch et al., who compared relative FDG uptake in patients with advanced CAD and impaired regional and global function before and after revascularization (54). Their study demonstrated that maintained FDG uptake in dysfunctional segments with reduced flow is associated with functional recovery after revascularization, whereas segments with concordantly decreased flow and metabolism do not recover after restoration of blood flow. Imaging with FDG for delineation of viability is superior to that achievable with thallium imaging (55-57). These studies have demonstrated that approximately 30% to 50% of segments failed to represent scar by delayed thallium imaging demonstrate uptake of FDG suggesting viability.

### Table 4. Flow-metabolism patterns in dysfunctional myocardium

<table>
<thead>
<tr>
<th>Blood flow</th>
<th>Glucose metabolism</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>+</td>
<td>Normal</td>
</tr>
<tr>
<td>Diminished</td>
<td>+</td>
<td>Mismatch (viability)</td>
</tr>
<tr>
<td>Diminished</td>
<td>Diminished</td>
<td>Match (necrosis)</td>
</tr>
</tbody>
</table>

### Table 3. Cardiac positron radiopharmaceuticals

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Radionuclide</th>
<th>Pharmaceutical</th>
<th>Physical Half-life</th>
<th>Production</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perfusion</td>
<td>Nitrogen-13</td>
<td>Ammonia</td>
<td>10 min</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td>Rubidium-82</td>
<td>Rubidium</td>
<td>76 seconds</td>
<td>Generator</td>
</tr>
<tr>
<td></td>
<td>Oxygen-15</td>
<td>Water</td>
<td>110 seconds</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>Glucose metabolism</td>
<td>Fluorine-18</td>
<td>Fluorodeoxyglucose</td>
<td>110 minutes</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>Fatty acid metabolism</td>
<td>Carbon-11</td>
<td>Acetate</td>
<td>20 minutes</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td>Carbon-11</td>
<td>Palmitate</td>
<td>20 minutes</td>
<td>Cyclotron</td>
</tr>
</tbody>
</table>
motion recovery. This finding is not surprising, because the gold standard for functional recovery may underestimate the presence of viable myocardium, especially in the epicardium. Revascularized segments with subendocardial infarction may show only little functional recovery but may benefit from improved oxygen supply, especially during stress to viable epicardial layers.

**Prognostic role of PET imaging**

Positron emission tomography also has been shown to have important prognostic implications based on the findings of viable versus nonviable myocardium. Patients who are identified as having scar based on PET who do not undergo revascularization have a 14% 1-year incidence of major adverse cardiac events compared with a 7% incidence in patients with scar who underwent revascularization. In contrast, patients with viable myocardium based on PET who did not undergo revascularization had a 1-year event rate of 47%, which was markedly reduced (to 11%) if patients underwent revascularization (56, 65-71). This is despite the fact that studies were performed in patients with very severe LV dysfunction. For example, in the study of Rohatgi et al., the pre-PET mean EF was 22% (56).

These data indicate that the mismatch pattern identifies a subgroup of patients at increased risk for cardiovascular complications. The prognostic information appears independent of the traditional markers, such as LV EF or the New York Heart Association (NYHA) classification, which were not different among the investigated subgroups. Survival was significantly higher in revascularized patients with mismatch.

DiCarli (7) reviewed PET studies comparing both therapy strategies in patients with mismatch. As shown in Figure 3, mismatch pattern was associated with a significantly better survival in all patient cohorts (71). Patients with severe LV dysfunction are at higher risk for complications associated with revascularization.

Dreyfus et al. (72) reported that the assessment of tissue viability in such patients before surgery improves the selection process for revascularization, with low perioperative mortality. Haas et al. confirmed this prognostic role for PET by comparing short-term and midterm survival after surgical revascularization in two groups of patients with three-vessel disease and impaired LV function (73). Whereas one group of patients was selected for surgery based on angiographic and clinical data, the second group consisted of patients selected based on evidence of tissue viability by PET. The latter group had significantly lower incidence of short-term and mid-term complications as well as significantly lower hospital mortality. The prediction of low perioperative complications is an important aspect in the selection process of patients with low LVEF for surgical revascularization, because the reported perioperative mortality of unselected patients averages around 10%. They also reported a 30-day hospital mortality of only 1.9% in more than 100 patients with LVEF, with less than 30% undergoing surgery after a PET-based selection process, which compares very favorably with the results in unselected patients.

**Free fatty acid imaging**

Free fatty acid imaging with Carbon-11 acetate may in fact be more sensitive in assessing viable myocardium compared with FDG (58-60). However, this tracer requires a cyclotron in addition to the assessment of the myocardial kinetics of washout, thereby making this somewhat less useful for most centers.

A single photon congener, β-methyl-β-123I-iodophenylpentadecanoic acid (BMIPP), has been used for identification of viable myocardium (61).

DiCarli et al. (62) demonstrated that size of the PET defect representative of hibernating myocardium was predictive of the functional recovery after revascularization. This is important because patients that have the poorest ventricular function are most at risk for perioperative morbidity or mortality but also are those that typically show the most improvement when they undergo revascularization. Analysis of data of patients shows that global LV function increases significantly after revascularization in patients with viable myocardium based on PET (56, 63).

Slart et al. (64) reported that N-13 ammonia PET showed a significant increase in nitrate-enhanced blood flow in viable myocardium, whereas blood flow remained unchanged after nitrate administration in nonviable myocardium similar Tc-99m-labeled perfusion agents.

In all studies, recovery of regional function after revascularization served as the gold standard for tissue viability. However, the criteria of viability have not yet been standardized and vary from study to study. Bax et al. (65), compared the diagnostic performance of various viability tests: PET proved to be the most sensitive method, whereas methods assessing contractile performance displayed greater specificity for wall
Tarakji et al. (74) reported that among systolic heart failure patients (LVEF < or =35%) referred for FDG PET, early intervention may be associated with improved survival irrespective of the degree of viability (74).

Centers that perform heart transplants often use PET to determine those patients in whom coronary artery bypass grafting (CABG) can be performed rather than transplantation. It has been the experience of several centers that approximately 30 to 50% of patients referred for transplantation have hibernating myocardium based on PET (75-77). These patients do well when revascularized.

Allman et al. (78) summarized the available prognostic data for viability tests in meta-analysis of 24 studies (more than 3000 patients). In patients with evidence of viability, revascularization was associated with an 80% reduction in annual mortality compared with medical treatment (16% vs. 3.2%). The benefit of revascularization was related to the extent of dysfunction in patients with evidence of viability, indirectly indicating the degree of hibernating myocardium. Patients without evidence of viability in dysfunctional segments did not benefit from revascularization (7.7% vs 6.2% annual mortality with and without revascularization, respectively).

These studies suggest that revascularization brings a survival benefit beyond wall motion enhancement or an increase in LVEF, possibly due to protection against sudden death, or protection from further remodeling and dilatation (Fig. 4). The question of possible survival benefit from CABG even in the absence of an increase in LVEF needs to be ascertained. Some patients with angina undergo CABG even without hope of likely improvement in LVEF (79). Documentation of ischemia in patients with symptoms, or episodes of exacerbation of heart failure and prediction of resolution of ischemic episodes after even limited revascularization, is a desirable aim.

Future prospects

It is not clear whether improvement of ventricular function, regional or global, is necessary for the patient’s benefit. Samady et al. (80) ascertained no difference in survival between ischemic cardiomyopathy patients who did or did not have improved LVEF following bypass surgery. In addition, postoperative improvement in angina and heart failure were similar between the two groups. Thus, even without improvement in ventricular systolic function, there may be important clinical benefits. Preservation of the small areas of viability detected by perfusion imaging techniques may improve clinical outcome by stabilizing the electrical milieu and preventing lethal arrhythmias, by preventing a subsequent myocardial infarction, and by improving symptoms and functional capacity through prevention of deleterious myocardial dilatation and remodeling (81). These concepts need further investigation.

With the continued aging of the population and the predicted greater prevalence of patients with chronic diseases such as congestive heart failure and LV dysfunction attributable to CAD, it will become increasingly important to identify patients who will benefit from interventions such as revascularization. It will be important to more accurately identify myocardial viability (2).
Currently available imaging techniques: stress-delayed, rest-delayed and reinjection thallium imaging, Te-99m sestamibi imaging, metabolic imaging with PET, dobutamine stress echocardiography, and MRI, are all helpful in making clinical decisions, but all have limitations. Larger, carefully conducted prospective studies will need to be performed to more effectively evaluate the accuracy of various tests alone or in combination, they will need to incorporate newer technologies. The combination of PET and SPECT with computerized tomography will allow establishing of the correlation between coronary anatomy and metabolic imaging, further improving the noninvasive assessment of patients with ischemic heart failure. In addition, newer procedures, such as therapeutic coronary angiogenesis and stem cell repair techniques, may revolutionize the way patients with these types of cardiovascular disease are managed (82, 83).

Nevertheless, one would expect that nuclear medicine techniques will continue to play an important role in assessment of myocardial viability in patients with advanced CAD and severely impaired LV function.

References


61. Tamaki N, Morita K, Tsukamota E, Kawai Y. Future aspects of myocardial viability by SPECT and PET in LV dysfunction. Demirkol M. O. Anadolu Kardiyol Derg 2008; 8: Özel Sayı 2; 60-70.


